Intracranial Efficacy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in Real-World Patients with Non-Small-Cell Lung Cancer and EGFR or ALK Alterations.

Cancers (Basel) · 2024 · PMC11011096 · PMID 38610927

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

A figure in the Supplementary Data of the IMpower150 study [ 24 ] showed a trend towards benefit in the 31 patients with ALK translocations who received ABCP or BCP.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.